Hwan Geun Choi
YOU?
Author Swipe
View article: Exploring Design Approaches for Reducing Viewers' Discomfort with Distressing Short-form Videos
Exploring Design Approaches for Reducing Viewers' Discomfort with Distressing Short-form Videos Open
The growing popularity of short-form video platforms and their reliance on algorithmic recommendations highlights the risk of viewers unintentionally encountering distressing content. Therefore, we investigated viewers' experiences with di…
View article: Modeling acute myocardial infarction and cardiac fibrosis using human induced pluripotent stem cell-derived multi-cellular heart organoids
Modeling acute myocardial infarction and cardiac fibrosis using human induced pluripotent stem cell-derived multi-cellular heart organoids Open
View article: Estimating Ground Reaction Forces (GRF) and Lower Extremity Joint Moment in Multiple Walking Environment Using Deep Learning
Estimating Ground Reaction Forces (GRF) and Lower Extremity Joint Moment in Multiple Walking Environment Using Deep Learning Open
Estimating Ground Reaction Forces (GRF) and Lower Extremity Joint Moment in Multiple Walking Environment Using Deep Learning
View article: Estimating Ground Reaction Forces (GRF) and Lower Extremity Joint Moment in Multiple Walking Environment Using Deep Learning
Estimating Ground Reaction Forces (GRF) and Lower Extremity Joint Moment in Multiple Walking Environment Using Deep Learning Open
Estimating Ground Reaction Forces (GRF) and Lower Extremity Joint Moment in Multiple Walking Environment Using Deep Learning
View article: New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation
New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation Open
View article: Supplementary Figure S2 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Supplementary Figure S2 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma Open
Supplementary Figure S2. EphA2 inhibitor-kinase interaction maps.
View article: Supplementary Table S1 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Supplementary Table S1 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma Open
Supplementary Table S1. The information of the melanoma patients for EphA2 analysis.
View article: Supplementary Table S2 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Supplementary Table S2 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma Open
Supplementary Table S2. Combination indices per method of Chou and Talalay.
View article: Data from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Data from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma Open
BRAFV600E is the most common oncogenic lesion in melanoma and results in constitutive activation of the MAPK pathway and uncontrolled cell growth. Selective BRAF inhibitors such as vemurafenib have been shown to neutralize oncog…
View article: Supplementary Table S2 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Supplementary Table S2 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma Open
Supplementary Table S2. Combination indices per method of Chou and Talalay.
View article: Supplementary Figure S1 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Supplementary Figure S1 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma Open
Supplementary Figure S1. Survival Curves for VEM resistant lines.
View article: Supplementary Figure S1 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Supplementary Figure S1 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma Open
Supplementary Figure S1. Survival Curves for VEM resistant lines.
View article: Supplementary Figure S4 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Supplementary Figure S4 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma Open
Supplementary Figure S4. EphA2 inhibitors suppressed the viability of VEM sensitive and resistant BRAF mutant cell lines and NRAS mutant cell lines.
View article: Supplementary Figure S5 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Supplementary Figure S5 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma Open
Supplementary Figure S5. ALW-II-41-27 suppresses in vivo tumor growth of both VEM sensitive and resistant melanomas.
View article: Supplementary Figure S4 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Supplementary Figure S4 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma Open
Supplementary Figure S4. EphA2 inhibitors suppressed the viability of VEM sensitive and resistant BRAF mutant cell lines and NRAS mutant cell lines.
View article: Supplementary Figure S2 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Supplementary Figure S2 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma Open
Supplementary Figure S2. EphA2 inhibitor-kinase interaction maps.
View article: Supplementary Figure S3 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Supplementary Figure S3 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma Open
Supplementary Figure S3. Fig. S3. Validation of EphA2 as the target of EphA2 inhibitors.
View article: Supplementary Table S1 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Supplementary Table S1 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma Open
Supplementary Table S1. The information of the melanoma patients for EphA2 analysis.
View article: Supplementary Figure S5 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Supplementary Figure S5 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma Open
Supplementary Figure S5. ALW-II-41-27 suppresses in vivo tumor growth of both VEM sensitive and resistant melanomas.
View article: Data from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Data from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma Open
BRAFV600E is the most common oncogenic lesion in melanoma and results in constitutive activation of the MAPK pathway and uncontrolled cell growth. Selective BRAF inhibitors such as vemurafenib have been shown to neutralize oncog…
View article: Supplementary Figure Legends from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Supplementary Figure Legends from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma Open
Supplementary Figure Legends
View article: Supplementary Figure Legends from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Supplementary Figure Legends from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma Open
Supplementary Figure Legends
View article: Supplementary Figure S3 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Supplementary Figure S3 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma Open
Supplementary Figure S3. Fig. S3. Validation of EphA2 as the target of EphA2 inhibitors.
View article: Supplementary Figure 3A-3B from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Supplementary Figure 3A-3B from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors Open
Supplementary Figure 3A-3B from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
View article: Supplementary Figure 5F from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Supplementary Figure 5F from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors Open
Supplementary Figure 5F from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
View article: Supplemental Figure legends from EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
Supplemental Figure legends from EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors Open
Supplemental Figure legends. This file contains the detailed descriptions of the supplementaal figures.
View article: Data from <i>EML4-ALK</i> Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
Data from <i>EML4-ALK</i> Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer Open
Purpose: The EML4-ALK fusion gene has been detected in ∼7% of Japanese non-small cell lung cancers (NSCLC). We determined the frequency of EML4-ALK in Caucasian NSCLC and in NSCLC cell lines. We also determined whether…
View article: Supplementary Table 1 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Supplementary Table 1 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors Open
Supplementary Table 1 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
View article: Supplementary Figure 7 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Supplementary Figure 7 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors Open
Supplementary Figure 7 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
View article: Supplemental Figures 1 - 7 from EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
Supplemental Figures 1 - 7 from EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors Open
Supplemental Figures 1 - 7. Figure S1. Sequence tracings from WZ4002 resistant Ba/F3 cells demonstrating EGFR L718Q, C797S and L844V mutations. Figure S2. EGFR Del19 Ba/F3 cells alone or expressing EGFR L718Q were treated with EGF. Figure …